Healthcare

Silence Therapeutics plc has entered into a separation agreement with its chief financial officer, Craig Tooman, concluding his tenure with a multi‑million‑dollar arrangement. The agreement, which becomes effective in mid‑December 2025, provides continued salary, a lump‑sum payment, and accelerated vesting of equity awards, underscoring …

BioRestorative Therapies has undergone a leadership transition following the resignations of two key executives, who assert they are owed severance payments. The disagreement stems from differing interpretations of whether recent changes in board composition triggered specific provisions in their employment agreements. The company has …

A surge in unplanned family health crises is reshaping the palliative care sector, forcing providers to adapt to a wave of late-stage enrollments from patients with no prior care arrangements. The shift comes as estranged relatives, often unprepared for sudden medical decisions, turn to …

Inhibrx Biosciences has secured a credit facility with a total commitment of $500 million and has drawn $100 million to support its clinical development programs. The agreement with Oxford Finance provides the company with the ability to draw an additional $225 million in $50 …

Price decline follows earnings release · Market reaction contrasts with financial results · Next catalyst: Full-year 2026 outlook update

Arcutis Biotherapeutics has expanded its board of directors with the addition of Christopher Peetz, a key executive from Mirum Pharmaceuticals. This appointment aligns with the company’s strategic focus on commercializing its ZORYVE franchise and advancing its pipeline in immuno-dermatology. As Arcutis continues to establish …

Cosmos Health has established a new class of preferred stock that contributes one hundred million votes, enabling board actions even when shareholder participation falls short of the quorum demanded by Nevada law. This step follows a recent annual meeting where only approximately 47% of …